Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of sacubitril-valsartan therapy is safe and effective among patients who are hospitalized for acute decompensated heart failure is unknown.
T h e ne w e ngl a nd jou r na l o f m e dicine A cute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. 1 Rates of short-term unplanned rehospitalization and death associated with acute decompensated heart failure are high (21% and 12%, respectively). 2 Despite multiple trials of promising therapies, the standard of care, which consists of decongestion with intravenous diuretics and hemodynamic support with vasodilators and inotropes, has remained largely unchanged during the past 45 years. [3] [4] [5] Sacubitril-valsartan is an angiotensin receptor-neprilysin inhibitor that is indicated for the treatment of patients with symptomatic heart failure with reduced ejection fraction. In the PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial, 6, 7 the use of sacubitril-valsartan resulted in a lower risk of death from cardiovascular causes or hospitalization for heart failure than the use of enalapril in this population. Patients who were eligible for inclusion in the PARADIGM-HF trial were ambulatory outpatients who had received an angiotensin-converting-enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB), at stable doses equivalent to a dose of enalapril of 10 mg daily, for a minimum of 4 weeks. In addition, the trial had sequential run-in periods during which all patients received high-dose enalapril and sacubitril-valsartan before they underwent randomization. Patients with acute decompensated heart failure, which was defined by the presence of signs and symptoms that may lead to the use of intravenous therapy, were excluded from the trial.
Whether the initiation of sacubitril-valsartan therapy is effective and safe among patients who are hospitalized for acute decompensated heart failure is unknown. 8 Therefore, we designed the PIONEER-HF (Comparison of Sacubitril-Valsartan versus Enalapril on Effect on NT-proBNP in Patients Stabilized from an Acute Heart Failure Episode) trial to assess the efficacy and safety of the initiation of sacubitril-valsartan therapy, as compared with enalapril therapy, after hemodynamic stabilization among patients who were hospitalized for acute decompensated heart failure.
Me thods

Trial Design
Details of the trial design have been published previously. 9 We conducted a multicenter, randomized, double-blind, active-controlled trial of the in-hospital initiation of sacubitril-valsartan therapy, as compared with enalapril therapy, among patients who had been admitted for acute decompensated heart failure with reduced ejection fraction. The trial protocol (available with the full text of this article at NEJM.org) was approved by ethics committees at participating centers. Novartis was the sole sponsor and conducted the trial in collaboration with the Duke Clinical Research Institute (DCRI) and the Thrombolysis in Myocardial Infarction (TIMI) Study Group.
The academic leadership committee (see the Supplementary Appendix, available at NEJM.org) designed the protocol, identified the participating centers, and oversaw implementation of the protocol in conjunction with the trial sponsor. United BioSource Corporation (UBC), a contract research organization, was involved in trial operations. All statistical analyses were completed by UBC and were verified independently by the DCRI and the sponsor. An independent data and safety monitoring board (see the Supplementary Appendix) monitored safety data during the trial. The first draft of the manuscript was written by the first author, and all the authors critically reviewed and revised the manuscript at every stage before acceptance. All the authors had full access to the data and vouch for the completeness and accuracy of the data and for the fidelity of the trial to the protocol.
Trial Patients
Patients 18 years of age or older were eligible for inclusion in the trial if they had a left ventricular ejection fraction of 40% or less and an N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration of 1600 pg per milliliter or more or a B-type natriuretic peptide (BNP) concentration of 400 pg per milliliter or more and had received a primary diagnosis of acute decompensated heart failure, including signs and symptoms of fluid overload. Patients were enrolled no less than 24 hours and up to 10 days after initial presentation to the hospital, while they were still hospitalized.
Before randomization, patients were required to be hemodynamically stable, which was defined by maintenance of a systolic blood pressure of at least 100 mm Hg for the preceding 6 hours, with no increase in the dose of intravenous diuretics and no use of intravenous vasodilators during the preceding 6 hours and no use of intravenous inotropes during the preceding 24 hours. A complete list of the inclusion and exclusion criteria is provided in Table S1 in the Supplementary Appendix. All the patients provided written informed consent.
Trial Procedures
Patients were randomly assigned to receive either sacubitril-valsartan or enalapril. Randomization was performed with the use of an interactive Web-based response system. The initial dose of sacubitril-valsartan (either 24 mg of sacubitril with 26 mg of valsartan or 49 mg of sacubitril with 51 mg of valsartan as a fixed-dose combination) or enalapril (either 2.5 mg or 5 mg) was administered orally twice daily, with dosing selected on the basis of the systolic blood pressure at randomization, according to a prespecified algorithm (Fig. S1 in the Supplementary Appendix). To ensure blinding, with each dose patients also received a placebo that resembled the other trial drug. Patients in the enalapril group received the assigned trial drug and placebo starting with the first dose. Patients in the sacubitril-valsartan group received two doses of placebo alone (with tablets that resembled both trial drugs), to ensure a washout period of a minimum of 36 hours before the initiation of sacubitril-valsartan, and then received the assigned trial drug and placebo starting with the third dose. All the patients were monitored for a minimum of 6 hours after the third dose was administered before they were discharged from the hospital.
During the 8-week trial period, the dose of sacubitril-valsartan was adjusted with a target of 97 mg of sacubitril with 103 mg of valsartan twice daily, and the dose of enalapril was adjusted with a target of 10 mg twice daily. Dose adjustment was guided by an algorithm that was based on the systolic blood pressure and by the investigator's assessment of side effects (Fig. S1 in the Supplementary Appendix). Follow-up visits were to be scheduled for weeks 1 and 2 and every 2 weeks thereafter. Hematologic, chemical, and biomarker analyses of blood and urine samples were performed at a central laboratory. The last dose of the assigned trial drug was administered on the morning of the week 8 visit.
Trial Outcomes
The primary efficacy outcome was the time-averaged proportional change in the NT-proBNP concentration from baseline through weeks 4 and 8. Key safety outcomes were the incidences of worsening renal function (an increase in the serum creatinine concentration of ≥0.5 mg per deciliter [≥44 μmol per liter] and a decrease in the estimated glomerular filtration rate of ≥25%), hyperkalemia (a serum potassium concentration of ≥5.5 mmol per liter), symptomatic hypotension, and angioedema. Any angioedema-like event that was reported by a site investigator was reviewed by an angioedema adjudication committee whose members were unaware of the treatment assignments (see the Supplementary Appendix). Secondary biomarker outcomes included time-averaged proportional changes in the high-sensitivity troponin T concentration, BNP concentration, and ratio of BNP to NT-proBNP. We also conducted analyses of exploratory clinical outcomes, including the incidence of a composite of death, rehospitalization for heart failure, implantation of a left ventricular assist device, inclusion on the list of patients eligible for heart transplantation, an unplanned visit for acute heart failure that led to the use of intravenous diuretics, an increase in the dose of diuretics of more than 50%, or the use of an additional drug for heart failure.
Statistical Analysis
We calculated that a sample of 882 patients would provide the trial with 85% power to detect an 18 percentage-point greater time-averaged proportional reduction in the NT-proBNP concentration, from the baseline value to the geometric mean of values obtained at weeks 4 and 8, in the sacubitril-valsartan group than in the enalapril group, at a two-sided significance level of 0.05. This calculation was based on the assumption of a ratio of the NT-proBNP concentration at week 8 as compared with baseline of 0.95 in the enalapril group, a geometric standard deviation of the log normal distribution of 0.85, and a rate at T h e ne w e ngl a nd jou r na l o f m e dicine which samples are missing or cannot be evaluated of 25%.
All efficacy analyses were performed according to the intention-to-treat principle, with the use of all available data through the 8-week trial period. The analyses were based on the likelihood method, with the assumption that data were missing at random. The analyses included all enrolled patients except those who underwent randomization inappropriately.
The primary analysis of the proportional change in the NT-proBNP concentration from baseline on a logarithmic scale was performed with the use of an analysis of covariance model, with adjustment for the baseline value. A similar method was used to analyze the secondary biomarker outcomes. The incidences of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema were calculated along with relative risks and associated 95% confidence intervals. Cumulative clinical-event rates were calculated according to the Kaplan-Meier method; the differences in clinical outcomes between the two treatment groups were assessed with the logrank test, and hazard ratios and associated 95% confidence intervals were calculated with a Cox proportional-hazards model. Confidence intervals for all outcomes except the primary efficacy outcome have not been adjusted for multiple comparisons, and therefore, inferences drawn from these intervals may not be reproducible. The consistency of treatment effect was examined across six prespecified subgroups and six additional exploratory subgroups. All analyses were performed with the use of SAS software, version 9.3 or higher (SAS Institute).
R esult s
Trial Population
From May 2016 to May 2018, a total of 887 patients were enrolled at 129 participating centers in the United States. A total of 6 patients (0.7%) underwent randomization inappropriately; these patients did not receive any doses of a trial drug and were prospectively omitted from all analyses. The efficacy analyses included 881 patients, of whom 440 were randomly assigned to receive sacubitril-valsartan and 441 to receive enalapril (Fig. 1) . The trial database was locked on August 21, 2018.
Patients were enrolled in the trial a median of 68 hours (interquartile range, 48 to 98) after initial presentation to the hospital. At the time of randomization, signs and symptoms of heart failure were highly prevalent; 61.7% of the patients had peripheral edema and 32.9% had rales on auscultation of the lungs. Baseline characteristics of the patients are shown in Table 1 , and in Table S2 in the Supplementary Appendix. The mean (±SD) age of the patients was 61±14 years; 635 patients (72.1%) were male, and 316 (35.9%) were black. The index hospitalization was for the first diagnosis of heart failure in 303 patients (34.4%). Of the 576 patients (65.4%) who had previously received a diagnosis of heart failure, 343 (59.5%) had had at least one hospitalization for heart failure during the previous year. At the time of admission to the hospital, 459 patients (52.1%) were not receiving treatment with an ACE inhibitor or ARB.
At randomization, the median systolic blood pressure was 118 mm Hg (interquartile range, 110 to 132), and 23.4% of the patients had a systolic blood pressure of less than 110 mm Hg. At screening, the median NT-proBNP concentration was 4812 pg per milliliter (interquartile range, 3050 to 8745) and the median BNP concentration was 1063 pg per milliliter (interquartile range, 718 to 1743). During the index hospitalization and before randomization, 814 patients (93.0%) received intravenous furosemide, 97 (11.0%) received care in an intensive care unit, and 68 (7.7%) received an intravenous inotrope. The median duration of the index hospitalization was 5.20 days (interquartile range, 4.09 to 7.24).
Trial Treatments and Follow-up
At least one dose of a trial drug was administered in 875 patients (439 in the sacubitril-valsartan group and 436 in the enalapril group); these patients were included in the safety analyses (i.e., analyses of adverse events). With the exclusion of discontinuation owing to death, the trial drug was discontinued prematurely in 87 patients (19.6%) in the sacubitril-valsartan group and in 90 patients (20.3%) in the enalapril group (Table S3 in the Supplementary Appendix). A total of 4 patients (3 in the sacubitril-valsartan group and 1 in the enalapril group) were lost to followup, with no data on vital status at 8 weeks; data for these patients were censored at a median of 37 days (Fig. 1) . By the week 8 visit, 243 patients (55.2%) in the sacubitril-valsartan group and 268 (60.8%) in the enalapril group were receiving the target dose of the assigned trial drug. Data for the primary efficacy outcome were available through week 8 for 349 patients (79.3%) in the sacubitril-valsartan group and for 348 patients (78.9%) in the enalapril group.
Primary Efficacy Outcome
The NT-proBNP concentration decreased in both treatment groups. The time-averaged reduction in the NT-proBNP concentration was significantly greater in the sacubitril-valsartan group than in the enalapril group; the ratio of the geometric mean of values obtained at weeks 4 and 8 to the baseline value was 0.53 in the sacubitril-valsartan group as compared with 0.75 in the enalapril group (percent change, −46.7% vs. −25.3%; ratio of change with sacubitril-valsartan vs. enalapril, 0.71; 95% confidence interval [CI], 0.63 to 0.81; P<0.001) (Fig. 2, and Table S4 in the Supplemen- T h e ne w e ngl a nd jou r na l o f m e dicine tary Appendix). The greater reduction in the NTproBNP concentration with sacubitril-valsartan than with enalapril was evident as early as week 1 (ratio of change, 0.76; 95% CI, 0.69 to 0.85).
The results remained robust in a multiple imputation analysis that was performed to account for missing data (ratio of change, 0.73; 95% CI, 0.64 to 0.82).
Secondary Efficacy and Safety Outcomes
The rates of worsening renal function, hyperkalemia, and symptomatic hypotension did not differ significantly between the sacubitril-valsartan group and the enalapril group (Table 2 ). Figure S2 in the Supplementary Appendix shows the mean serum creatinine concentration, potassium concentration, and systolic blood pressure throughout the trial period in each group; Table S5 in the Supplementary Appendix shows the number of patients who had a systolic blood pressure of less than 100 mm Hg at each time point in each group. On blinded adjudication, there was one confirmed angioedema event in the sacubitril-valsartan group (in a white patient) and there were six in the enalapril group (all in black patients) ( Table 2) . Secondary biomarker outcomes and exploratory clinical outcomes are shown in Table 2 . Table S6 in the Supplementary Appendix shows the most common adverse events (occurring in >5% of the patients in either treatment group). The rate of permanent discontinuation of the trial drug owing to any adverse event did not differ significantly between the two treatment groups (Table S3 in the Supplementary Appendix).
Subgroup Analyses
Results of analyses of subgroups that were defined according to demographic and clinical characteristics of interest reflected a consistently beneficial effect of sacubitril-valsartan, as compared with enalapril, with regard to the primary efficacy outcome (Fig. 3) . In addition, subgroup analyses showed no significant differences between the two treatments with regard to the key safety outcomes (Fig. S3 in the Supplementary Appendix).
Discussion
The PIONEER-HF trial was performed to evaluate the use of a neprilysin inhibitor added to a reninangiotensin system inhibitor, as compared with a renin-angiotensin system inhibitor alone, in the treatment of patients who were hospitalized for acute heart failure. The initiation of sacubitrilvalsartan therapy after hemodynamic stabilization led to a greater reduction in the NT-proBNP concentration than enalapril therapy, a difference that was evident by the first week. The beneficial effect of sacubitril-valsartan on the concentration of NT-proBNP, which is a biomarker of neurohormonal activation, hemodynamic stress, and subsequent cardiovascular events, was accompanied by a reduction in the concentration of high-sensitivity cardiac troponin T, which is a biomarker of myocardial injury associated with abnormalities of cardiac structure and function and with a worse prognosis among patients with heart failure. The rates of renal dysfunction, hyperkalemia, and symptomatic hypotension did not differ significantly between the sacubitril-valsartan group and the enalapril group. Furthermore, in an analysis of exploratory clinical outcomes, the in-hospital initiation of sacubitril-valsartan therapy was associated with a lower rate of rehospitalization for heart failure at 8 weeks than enalapril therapy.
The results of the PIONEER-HF trial extend the evidence base regarding the use of sacubitril-valsartan to populations for which there had been limited or no data, including patients who are hospitalized for acute decompensated heart failure, patients who have new heart failure, patients who have not been exposed to high doses of guideline-directed medications for heart failure, and patients who are not receiving conventional renin-angiotensin system inhibitors. 8 In addition, 35.9% of the patients in our trial identified as black, and there is limited evidence from previous clinical studies regarding the use of sacubitril-valsartan among black patients. The favorable effect of sacubitril-valsartan, as compared with enalapril, was evident from the in-hospital initiation of treatment and continued to be present during the transition to home and throughout the subsequent "vulnerable period," during which morbidity and mortality among patients with acute decompensated heart failure remain high.
The finding that the rates of renal dysfunction, hyperkalemia, and symptomatic hypotension did not differ significantly between the sacubitril-valsartan group and the enalapril group is reassuring, especially among patients with acute decompensated heart failure, who are at a high risk for hemodynamic instability. In addition, in the sacubitril-valsartan group, there was only one case of angioedema, with no cases among black patients. Results from previous trials of sacubitril-valsartan, most notably the PARADIGM-HF trial, were limited to ambulatory outpatients who had received established high doses of an ACE inhibitor or ARB, as well as the highest doses of enalapril and sacubitril-valsartan during sequential single-blind run-in periods before randomization. The PIONEER-HF trial made use of the lowest starting dose of sacubitril-valsartan (24 mg of sacubitril with 26 mg of valsartan), with which there was less experience. 7, 10 The PIONEER-HF trial set specific requirements for the in-hospital initiation of sacubitril-valsartan therapy. Patients were required to have had a systolic blood pressure of at least 100 mm Hg for the preceding 6 hours, with no increase in the dose of intravenous diuretics and no use of intravenous vasodilators during the preceding 6 hours and no use of intravenous inotropes during the preceding 24 hours. Sacubitril-valsartan therapy was initiated at a low dose among patients with lower systolic blood pressure, and the dose was adjusted according to a prespecified algorithm. A washout period of 36 hours was used to ensure that patients who had previously been taking an ACE inhibitor or ARB did not have any overlapping medication effects. Despite these precautions, approximately 20% of the patients in each 
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T h e ne w e ngl a nd jou r na l o f m e dicine treatment group had discontinued treatment by 8 weeks, in most cases because of an adverse event.
Taken together, these considerations suggest that the initiation of any neurohormonal agent in this population should be performed cautiously.
There are several limitations of our trial. The in-hospital initiation phase, which included the provision of placebo alone for the first two doses in the sacubitril-valsartan group and then mandatory observation for 6 hours after the third dose, may have prolonged the length of stay. These elements of the protocol were necessary to preserve blinding, maintain protocol consistency, and ensure patient safety. In addition, approximately 0.5% of the patients were lost to follow-up and 15% had missing data on the NT-proBNP concentration, although the results for the primary efficacy outcome remained significant in an analysis with multiple imputation.
In conclusion, among patients who were hospitalized for acute decompensated heart failure, the initiation of sacubitril-valsartan therapy resulted in a significantly greater reduction in the NT-proBNP concentration than enalapril therapy. There were no significant differences between the sacubitril-valsartan group and the enalapril group with regard to the rates of renal insufficiency, hyperkalemia, symptomatic hypotension, and angioedema. † Worsening renal function was defined by an increase in the serum creatinine concentration of 0.5 mg per deciliter or more (≥44 μmol per liter) and a decrease in the estimated glomerular filtration rate of 25% or more. ‡ Shown are data on the time-averaged proportional change, from the baseline value to the geometric mean of values obtained at weeks 4 and 8. § Hazard ratios and associated 95% confidence intervals were calculated with a Cox proportional-hazards model. Confidence intervals have not been adjusted for multiple comparisons, and therefore, inferences drawn from these intervals may not be reproducible. ¶ The outcome of a composite of serious clinical events was added to the list of exploratory clinical outcomes in May 2018, before the database was locked and unblinding occurred. This end point included death, rehospitalization for heart failure, implantation of a left ventricular device, and inclusion on the list of patients eligible for heart transplantation. Shown are data on the time-averaged proportional change in the NT-proBNP concentration, from the baseline value to the geometric mean of values obtained at weeks 4 and 8, with each treatment according to subgroup. Information on race was reported by the patient. ACE denotes angiotensin-converting enzyme, ARB angiotensin-receptor blocker, GFR glomerular filtration rate, and NYHA New York Heart Association. 
